|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| [3. pielikums](http://www.likumi.lv/wwwraksti/2016/034/104/P3.DOCX" \o "Atvērt citā formātā) Ministru kabineta 2016. gada 16. februāra noteikumiem Nr. 104    **Epidemioloģiski nozīmīgu baktēriju uzskaites veidlapa stacionārās ārstniecības iestādēs**   |  |  | | --- | --- | | Iestādes nosaukums |  |      |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Kods |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |      |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Pārskata periods | |  | |  | |  | | | |  | | (gads) | |  | | (ceturksnis) | | | |  | | Kopējais pacientu skaits ar pirmreizēji izdalītu baktēriju | | t. sk. intensīvās terapijas nodaļās\* | | t. sk. slimo jaundzimušo nodaļās\* | t. sk. paraugs ņemts skrīninga\*\*izmeklējumam | | Pret meticilīnu rezistents*Staphylococcusaureus* (MRSA) | |  | |  | |  |  | | Pret vankomicīnu rezistents*Staphylococcus aureus* (VRSA) | |  | |  | |  |  | | Pret vankomicīnu rezistents *Enterococcus*(VRE) | |  | |  | |  |  | | *Clostridium difficile* | |  | |  | |  |  | | Pret karbapenēmiem rezistents*Acinetobacter spp./Acinetobacter baumannii* | |  | |  | |  |  | | Plaša spektra beta-laktamāzi*(ESBL*), t. sk. karbapenemāzi, producējošas gramnegatīvas nūjiņas | |  | |  | |  |  | | Citas\_\_\_\_\_\_\_\_\_ | |  | |  | |  |  | | Kopā | |  | |  | |  |  |   Piezīmes.  1. \* Pirmais pozitīvais paraugs.  2. \*\* Augsta riska grupas pacientu izmeklēšana.   |  |  |  |  |  | | --- | --- | --- | --- | --- | |  |  |  |  |  | | (amats) |  | (vārds, uzvārds) |  | (tālruņa numurs) |      |  |  |  | | --- | --- | --- | | 20\_\_. gada.\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |  | Paraksts \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | |  |